What this means in brief
- US prices for GLP-1 weight loss drugs are being cut for government programmes and a new TrumpRx cash option, with figures clustered between about $149 and $350 a month and a $50 co-pay cap for Medicare.
That narrows the price gap that Trump had used to argue Americans were overpaying compared to Europeans. A smaller gap means less incentive to push UK prices higher.
UK prices increased in September and now follow UK-specific mechanics, including manufacturer rebates and pharmacy mark-ups by dose. Those do not change because of a US deal. See our explainer: What will the new price of Mounjaro be after September’s hike?
Bottom line for SlimrChatters: There is no new signal of further UK price increases resulting from Trump’s announcement. Keep doing the sensible UK things — compare pharmacies, watch dose-level pricing, and share updates in the forum.
What exactly was announced in the US
The White House says Eli Lilly and Novo Nordisk (the makers of Mounjaro and Wegovy) agreed to reduce what Americans pay for GLP-1s. The plan expands Medicare and Medicaid coverage for weight loss use, caps Medicare co-pays at $50, and introduces a TrumpRx route for cash buyers with starting prices ranging from $149 to $350.
This follows the May “most-favoured-nation” (MFN) executive order that aimed to align US prices with the lowest paid in peer countries. The framing is bringing US prices down, not pushing other countries up.
Why this lowers, not raises, UK price-hike risk
For months, the argument from Washington was that Americans were paying far more than Europeans for the same drugs. Yesterday’s step cuts US prices and closes that gap. A smaller gap removes the political pressure point that previously made UK readers wonder if our prices would be forced higher.
If you want the earlier context, here is our May piece that asked the question many of you raised: Will Trump raise UK Mounjaro and Wegovy prices?
How UK pricing actually works after September
UK private prices were reset in September and now follow two UK-specific levers:
Rebates from the manufacturer that create a “discount price” below the list price.
Pharmacy mark-ups that tend to be pounds per dose rather than a fixed percentage.
That is why prices differ by pharmacy and dose, and why a US political deal does not automatically change what you pay here. Our detailed explainer is here: What will the new price of Mounjaro be after September’s hike?
SlimrChat’s take
Based on the information available so far, we believe further UK price increases resulting from Trump’s policy are unlikely. The US announcement cuts American prices, narrows the cross-market gap and expands US coverage. UK patient prices remain driven by UK rebates, pharmacy mark-ups and supply — not US headlines. We will keep tracking real UK prices dose by dose, with your help.
Further reading and viewing
White House fact sheet on MFN deal and price points (Nov 6, 2025).
- CNBC coverage of the announcement from President Trump
- Will Trump raise UK Mounjaro and Wegovy prices?
What will the new price of Mounjaro be after September’s hike?
Join the discussion
Tell us what you are seeing on UK prices by dose, delivery times and any discounts in the SlimrChat forum.